CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 87 enrolled / 87 target
Drug / intervention
Cannabis +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04827992
NCT04827992N/ACompletedOn Track (1.5/mo)Completion was 14mo ago
CompareCT.gov

Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain

Massachusetts General Hospital·interventional·Posted Apr 1, 2021·Updated Jun 24, 2026

In Brief

A clinical study evaluating Cannabis and Prescription Opioid Taper Support (POTS) for Opioid Use and 2 related conditions. Completed, enrolled 87 participants across 3 sites.

Detailed Summary

This study will use a randomized controlled design to test whether medical marijuana use by adults on high-dose chronic opioid therapy (COT) for chronic non-cancer pain is associated with reduced opioid dose and improved pain intensity and interference when added to a 24-week behavioral intervention (POTS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid Use, Pain, Marijuana Use
CountriesUnited States
CollaboratorsCambridge Health Alliance, MaineHealth, National Institute on Drug Abuse (NIDA)

Timeline

N/ACompletedFinished
20222023202420252026
First PostedApr 1, 2021
Enrollment StartAug 23, 2021
Primary CompletionMay 1, 2025
Study CompletionOct 31, 2025
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 5.3 years ago

Arms & Interventions

Cannabis (CB)experimental

Participants assigned to the cannabis group were allowed to initiate cannabis use immediately. Participants selected cannabis product type(s), dose(s), and frequency of use from commercial sources. All study participants were offered weekly group Prescription Opioid Taper Support (POTS), a behavioral intervention promoting pain self-management and gradual, voluntary opioid tapering, for 24 weeks.

Drug: CannabisBehavioral: Prescription Opioid Taper Support (POTS)
Waitlist (WL)active_comparator

Participants assigned to the waitlist control group agreed to delay cannabis use for 24 weeks. All study participants were offered weekly group Prescription Opioid Taper Support (POTS), a behavioral intervention promoting pain self-management and gradual, voluntary opioid tapering, for 24 weeks.

Behavioral: Prescription Opioid Taper Support (POTS)

Interventions

Cannabisdrug

Participants assigned to the cannabis group were allowed to initiate cannabis use immediately. Participants selected cannabis product type(s), dose(s), and frequency of use from commercial sources.

Prescription Opioid Taper Support (POTS)behavioral

All participants were offered weekly group Prescription Opioid Taper Support (POTS) sessions for 24 weeks. POTS is behavioral intervention promoting pain self-management and gradual, voluntary opioid tapering. This intervention was adapted for this trial to include group-based delivery. Sessions are one hour delivered via teleconference and incorporated cognitive behavioral, mindfulness-based, and motivational interviewing strategies.